Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | VHL | P40337 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25365732 | 1.00 | RIPK1 (0.42) | RIPK1SMYD2PIK3CDCYP3A4HTT | |
| SCHEMBL18587707 | 1.00 | RIPK1 (0.42) | RIPK1SMYD2PIK3CDCYP3A4HTT | |
| SCHEMBL25364479 | 1.00 | RIPK1 (0.42) | RIPK1SMYD2PIK3CDCYP3A4HTT | |
| SCHEMBL15345576 | 0.89 | CYP1A2 (0.41) | RIPK1SMYD2CYP3A4POLB | |
| SCHEMBL29035403 | 0.89 | CYP1A2 (0.41) | RIPK1SMYD2CYP3A4POLB | |
| SCHEMBL5152627 | 0.89 | CYP1A2 (0.41) | RIPK1SMYD2CYP3A4POLB | |
| SCHEMBL5152621 | 0.89 | CYP1A2 (0.41) | RIPK1SMYD2CYP3A4POLB | |
| SCHEMBL5150301 | 0.89 | CYP1A2 (0.41) | RIPK1SMYD2CYP3A4POLB | |
| SCHEMBL28396275 | 0.89 | CYP1A2 (0.41) | RIPK1SMYD2CYP3A4POLB | |
| SCHEMBL18587235 | 0.87 | SMYD2 (0.36) | RIPK1SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894048-B2 | Antitumor drug for intermittent administration of FGFR inhibitor | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-10835536-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3023101-B1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190183897-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-20 | — | — | US | disclosed |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3023100-B1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | TAIHO PHARMACEUTICAL CO LTD (JP) | 2019-03-13 | — | — | EP | disclosed |
| US-20190015417-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-17 | — | — | US | disclosed |
| US-20150322044-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| WO-2015171722-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015171757-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | WO | disclosed |
| EP-2925741-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2015-10-07 | — | — | EP | disclosed |
| US-9108973-B2 | 3,5-disubstituted alkynylbenzene compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO.,LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-2657233-B1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-08-27 | — | — | EP | disclosed |
| WO-2014078609-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-2657233-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-10-30 | — | — | EP | disclosed |
| WO-2011088045-A1 | AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE | AMBIT BIOSCIENCES CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | RIPK1 2388/4885SMYD2 4432/4885PIK3CD 2141/4885 |
| US-20190183897-A1 | ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | RIPK1 1064/4885SMYD2 2479/4885PIK3CD 242/4885 |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | RIPK1 2388/4885SMYD2 4432/4885PIK3CD 2141/4885 |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | RIPK1 2388/4885SMYD2 4432/4885PIK3CD 2141/4885 |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | RIPK1 2388/4885SMYD2 4432/4885PIK3CD 2141/4885 |
| US-20190015417-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | FGFR1, FGFR3, FGFR4 | RIPK1 1869/4885SMYD2 1784/4885PIK3CD 883/4885 |
| US-10894048-B2 | Antitumor drug for intermittent administration of FGFR inhibitor | FGFR1, FGFR3, FGFR2 | RIPK1 1064/4885SMYD2 2479/4885PIK3CD 242/4885 |
| US-20140343035-A1 | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | NFXL1, ZFX, CXXC5 | RIPK1 3600/4885SMYD2 439/4885PIK3CD 3958/4885 |
| US-20150322044-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | RIPK1 2388/4885SMYD2 4432/4885PIK3CD 2141/4885 |
| US-10835536-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | FGFR1, FGFR3, FGFR4 | RIPK1 1869/4885SMYD2 1784/4885PIK3CD 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.